4 completed, 3 terminated. 6 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 3, Terminated 3 |
| Phase 2 | 3 | Terminated 2, Completed 1 |
Follow ViaCyte: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1D VCTX211 - Diabetes Mellitus, Diabetes Mellitus, Type 1 | Phase 1 | Terminated | CRISPR Therapeutics AG | 5 | 2023-01-20 | 2026-05-07 |
| An Open-Label, FIH Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With T1D VCTX210A unit - Diabetes Mellitus, Diabetes Mellitus, Type 1 | Phase 1 | Completed | CRISPR Therapeutics AG | 7 | 2022-01-24 | 2023-06-26 |
| A Study to Evaluate Safety, Engraftment, and Efficacy of VC-01 in Subjects With T1 Diabetes Mellitus VC-01 Combination Product - Type 1 Diabetes | Phase 1 / Phase 2 | Terminated | ViaCyte | 31 | 2019-06-25 | 2023-10-18 |
| A Safety, Tolerability, and Efficacy Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus and Hypoglycemia Unawareness VC-02 Combination Product - Type 1 Diabetes Mellitus With Hypoglycemia | Phase 1 / Phase 2 | Completed | ViaCyte | 49 | 2017-07-06 | 2024-12-03 |
| A Safety and Tolerability Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus VC-02 Combination Product (aka PEC-Direct) - Type 1 Diabetes Mellitus | Phase 1 | Completed | ViaCyte | 3 | 2017-07-05 | 2018-10-18 |
| One-Year Follow-up Safety Study in Subjects Previously Implanted With VC-01™ Type 1 Diabetes Mellitus | Completed | ViaCyte | 51 | 2016-11-07 | 2024-04-23 | |
| A Safety, Tolerability, and Efficacy Study of VC-01™ Combination Product in Subjects With Type I Diabetes Mellitus VC-01™ Combination Product - Type 1 Diabetes Mellitus | Phase 1 / Phase 2 | Terminated | ViaCyte | 19 | 2014-09-01 | 2022-03-24 |
Diabetes Mellitus, Type 1 (6) · Autoimmune Diseases (2) · Diabetes Mellitus (2) · Endocrine System Diseases (2) · Glucose Metabolism Disorders (2) · Immune System Diseases (2) · Metabolic Diseases (2)
Canada (5) · United States (3) · Belgium (1)
Manasi Jaiman, MD, MPH (2) · Sandeep Soni, MD (2) · Gautham Marigowda (1) · Manasi Jaiman, MD (1)
PMID 42023429, PMID 29317381, PMID 29420708, PMID 34193595, PMID 34861146, PMID 35028608, PMID 37528526, PMID 38012450